PINHONBIO® EUK-134: bring analytical identity into the formulation brief

A defined material for a defined experiment

A development team needs to know what is entering the prototype before it can interpret the result. PINHONBIO® EUK-134 gives the New Actives collection a defined manganese-complex ingredient whose identity and assay can be connected to analytical records.

Its editorial interest lies in that connection: a named material, supporting identity data and a controlled trial can produce a more useful development record than a percentage alone. This brief considers how to make that record part of formulation work.

The confirmed technical profile

PINHONBIO lists the material as PH-XPNS 004. The published specification separates the HPLC assay from identification using LC-MS and HPLC. These establish raw-material acceptance dimensions, rather than a finished-product performance result.

Give the analytical file a job

Link the accepted specification, sample identification and batch record to the prototype before testing begins. Decide which analytical observations will be needed at the end of the study. That helps distinguish an incorporation problem from a change in material content or an issue with the measurement itself.

Keep a representative analytical example separate from evidence for the lot being evaluated. The formal COA belongs to its corresponding purchased batch; the sample and the later production material should be traceable through the development record.

Observe the whole system

The listed raw-material color makes appearance an obvious observation in early trials. Measure the prototype against a matched base, and include uniformity, clarity or precipitation where relevant. Review the selected solvents, surfactants, electrolytes, preservatives and other actives together.

A material that appears incorporated on day one still needs assessment through the intended process, storage conditions and primary pack. Agree on process guidance with the technical team rather than adopting a generic solubility, pH or temperature rule.

From a serum or cream concept to an evaluation

A serum development study can start with appearance, uniformity and compatibility in the selected base. A cream study can connect those observations to its emulsion process and intended pack. These are proposed evaluation contexts, not confirmation that a particular formulation has already passed testing.

If the project intends an antioxidant or other protection positioning, define the relevant finished-product endpoint and study before choosing claim wording. This brief reports no ingredient efficacy test or validated use level, and ingredient assay should not be treated as the claim evidence.

Start small and keep the record connected

The supplier lists 1 g evaluation and 100 g trial quantities, with 1 kg and 5 kg commercial quantities. These are listed supply options, not a declared minimum order. Use a small trial to resolve the incorporation and analytical questions before planning scale-up.

Request the specification/TDS, SDS and applicable HPLC and LC-MS files with your sample inquiry. Include the intended process, pack and market. Keep a clear handoff between material qualification, formula testing and the decision to proceed.

Sources & scope

• PINHONBIO: EUK-134 identity, HPLC/LC-MS documentation and evaluation supply

Supplier material reviewed October 4, 2026. General evaluation recommendations are editorial perspectives, not reported PINHONBIO test results.

Related reading